acorda-therapeutics
(2)
Ron Cohen
Ron Cohen, M.D., is a biotech entrepreneur with a 30-year record of building companies that ship medicines for the nervous system. He founded Acorda Therapeutics in 1995 from his apartment and grew it into a public company that brought multiple sclerosis and Parkinson's therapies to market. After Acorda's sale to Merz in 2024, he evaluated roughly two dozen startups before taking the CEO seat at Oryon Cell Therapies in March 2026, a Belmont, Massachusetts company developing autologous neuron replacement therapy for Parkinson's. He is a past Chair of the Biotechnology Innovation Organization (BIO).
Rick Batycky
Rick Batycky is a chemical engineer turned biotech founder who has spent two decades coaxing medicines into the lungs. As President and CEO of Nocion Therapeutics, he is developing a new class of charged sodium channel blockers built to silence overactive sensory neurons and finally quiet refractory chronic cough. Before Nocion he co-founded Civitas Therapeutics, revived a dormant inhalation platform, and carried the dry-powder levodopa therapy Inbrija through to FDA approval as Acorda's CTO.